Cytarabine (HCl)
Overview
Categories
- 8 Antineoplastics, immunomodulators and drugs used in palliative care
Primary Characterstics
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Cytarabine (HCl)'s dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 100 mg/sq.meter | 180 (183) | As recommended. | IV Inf | For 5 days. Repeated every 2 weeks total 12 doses |
Paedriatic Dosage (20kg)
|
| 70 to 200 mg/sq.meter | 140 (135) | 24 hourly | Intra Venous | Maintenance for 2-5 days per month |
| 200 mg/sq.meter | 370 (367) | 24 hourly | Intra Venous | Initially for 5 days for induction per 2 weeks |
Neonatal Dosage (3kg)
|
| No data regarding the neonatal dosage details of Cytarabine (HCl) is available. |
High Risk Groups
Back to top
Warning / Precautions
Cytarabine should be used with caution and in low doses in patients with impaired liver, kidneys or with pre-existing drug induced bone marrow suppression. It is not recommended for use in pregnant or nursing women.
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Cytarabine (HCl)
Back to top
Manufacturers of
Cytarabine (HCl)
in Pakistan
Back to top
Previous Drug Generic - Next Drug Generic